Partnership to Aid Access to Man-made FVIII for Patients in China
GenScript ProBio and Neoletix Biotechnology have entered into an agreement for clinical and commercial production of a lab-made version…
Articles by Marisa Wexler, MS
Dosing Begins in Trial of Efanesoctocog Alfa in Boys With Severe Hemophilia A
A first patient has been dosed in XTEND-Kids, a Phase 3 clinical trial evaluating the safety and efficacy of the…
Hemophilia Carriers at High Risk for Heavy Bleeding After Childbirth
Women who are hemophilia carriers are at a higher risk of experiencing heavy bleeding after giving birth, particularly those…
Survey on COVID-19 and Mental Health Opens in UK, US and Germany
A research study is asking people with hemophilia and other inherited bleeding disorders living in the U.K., U.S., or…
Experts Identify Unique Hemophilia Challenges, Propose Ways to Overcome
People with mild to moderate hemophilia, in particular women with the disease, face unique challenges, many that are specifically…
Low Risk of Developing Inhibitors Found for Nuwiq Patients
Treatment with Octapharma‘s Nuwiq is associated with a low risk of developing inhibitors — antibodies that prevent the medication…
Hemlibra Can Help Manage Bleeding in AHA, Study Finds
Treatment with Hemlibra (emicizumab) can help to effectively manage bleeding in individuals with acquired hemophilia A (AHA), according…
MarzAA Shows Promise in Hemophilia Animal Models
The investigational medication marzeptacog alfa activated (MarzAA) showed promise at stopping bleeding in animal models of hemophilia. The findings were…
Eloctate Can Induce Faster Immune Tolerance Than Other Regimens
Eloctate can induce immune tolerance in people with hemophilia A more quickly than other regimens, a study suggests.
Fresh Look at Mechanism Finds ‘Important Role’ in Factor VIII Regulation
A mechanism largely left unexplored was shown to help regulate factor VIII (FVIII) — the clotting protein that is missing…